Last reviewed · How we verify
ABSK021 with fasted state — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ABSK021 with fasted state (ABSK021 with fasted state) — Abbisko Therapeutics Co, Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ABSK021 with fasted state TARGET | ABSK021 with fasted state | Abbisko Therapeutics Co, Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ABSK021 with fasted state CI watch — RSS
- ABSK021 with fasted state CI watch — Atom
- ABSK021 with fasted state CI watch — JSON
- ABSK021 with fasted state alone — RSS
Cite this brief
Drug Landscape (2026). ABSK021 with fasted state — Competitive Intelligence Brief. https://druglandscape.com/ci/absk021-with-fasted-state. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing